

**Technology Appraisal Committee Meeting (Committee C)**  
**Level 1A, Piccadilly Plaza, Manchester, M1 4BT**

**Minutes:** Confirmed

**Date and Time:** Tuesday 27 November 2018

The names of all committee members present for any part of the meeting are listed below. Part attendance is indicated by noting the numbers of the minutes they were present for.

<b>Present:</b>	1. Andrea Manca	Present for notes 1 to 6
	2. Andrew Renehan	Present for all notes
	3. David Chandler	Present for all notes
	4. Derek Ward	Present for all notes
	5. Gail Coster	Present for notes 1 to 12
	6. Iain McGowan	Present for all notes
	7. John Hampson	Present for all notes
	8. Judith Wardle	Present for all notes
	9. Kamal Balakrishnan	Present for notes 1 to 12
	10. Matt Stevenson	Present for all notes
	11. Michael Chambers	Present for notes 1 to 6 and 13 to 16
	12. Natalie Hallas	Present for all notes
	13. Dr Nigel Langford	Present for all notes
	14. Dr Paul Tappenden	Present for all notes
	15. Dr Peter Selby	Present for all notes
	16. Dr Prithwiraj Das	Present for all notes
	17. Dr Richard Nicholas	Present for all notes
	18. Dr Robert Forsyth	Present for notes 1 to 12
	19. Dr Rubin Minhas	Present for all notes
	20. Ms Stella O'Brien	Present for all notes
	21. Prof Stephen O'Brien	Present for notes 7 to 18
	22. Ms Ugochinyere Nwulu	Present for all notes

**In attendance:**

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes

Stephanie Callaghan	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Pratit Shah	Administrator, National Institute for Health and Care Excellence	Present for all notes
Portia Dodds	Administrator, National Institute for Health and Care Excellence	Present for notes 1 to 6
Abitha Senthinathan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 6
Alexander Filby	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 6
Lorna Dunning	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 7 to 12
Nicola Hay	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 7 to 12
Julia Sus	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 13 to 16
Sally Doss	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 13 to 16
<b>Non-public attendees:</b>		
Isaac Corro Ramos	ERG Representative	Present for notes 1 to 3
Rob Riemsma	ERG Representative	Present for notes 1 to 3
Angela Stainthorpe	ERG Representative	Present for notes 7 to 8
Nigel Fleeman	ERG Representative	Present for notes 7 to 8
Rachel Houten	ERG Representative	Present for notes 7 to 8
Daniel Gallacher	ERG Representative	Present for notes 13 to 14

Felix Achana	ERG Representative	Present for notes 13 to 14
Peter Clark	CDF Clinical Lead	Present for notes 7 to 18
Claire Harrison	Clinical Expert	Present for notes 1 to 3
Maz Campbell-Drew	Patient Expert	Present for notes 1 to 3
Julia Scarisbrick	Clinical expert	Present for notes 7 to 8
Sean Whittaker	Clinical expert	Present for notes 7 to 8
Teresa Kelly	Patient expert	Present for notes 7 to 8
Andrew Stott	Patient expert	Present for notes 7 to 8
Dawn Lee	Company representative	Present for notes 1 to 3
Adam Craig	Company representative	Present for notes 1 to 3
Tanja Podkonjak	Company representative	Present for notes 7 to 8
Holly Cranmer	Company representative	Present for notes 7 to 8
Dimitra Alexiou	Company representative	Present for notes 13 to 14
Sukhdip Boughan	Company representative	Present for notes 13 to 14
Leslie Hays	NICE Observer	Present for all notes
Jamie Elvidge	NICE Observer	Present for notes 1 to 12
Linda Landells	NICE Observer	Present for notes 13 to 18
Hayley Sharpe	NICE Observer	Present for notes 1 to 12
Sarah Bromley	NICE Observer	Present for notes 1 to 12
Connor Rodgers	NICE Observer	Present for notes 1 to 12
Emily Carter	External Observer	Present for all notes
Mandy Tonkinson	NICE observer	Present for notes 7 to 12

## **Notes**

### **Any other Business**

1. None

### **Appraisal of Pacritinib for treating myelofibrosis [ID880]**

#### **Part 1 – Closed session**

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from CTI BioPharma.
3. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
  - 3.1. Claire Harrison declared a non-personal specific financial interest as she is involved in research projects related to myelofibrosis therapy.
    - 3.1.1. It was agreed that this declaration would not prevent Claire Harrison from participating in this section of the meeting.
  - 3.2. Maz Campbell-Drew declared a declared a personal specific non-financial interest as she is involved in patient forum for patients with myelofibrosis.
    - 3.2.1. It was agreed that this declaration would not prevent Maz Campbell-Drew from participating in this section of the meeting
  - 3.3. Stephen O'Brien declared a non-personal specific financial interest as he acted as a chair of a data monitoring committee for a Pacritinib study and did not attend this appraisal due to this conflict.
  - 3.4. No further conflicts of interest were declared for this appraisal.

#### **Part 2 – Closed session (company representatives, clinical and patient experts and ERG were asked to leave the meeting)**

4. The committee discussed confidential information submitted as part of this appraisal.
5. The committee decision was based on consensus.
6. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with

their decisions.

## **Appraisal of Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma [ID1190]**

### **Part 1 – Open session**

7. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Takeda Ltd.
8. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
  - 8.1. Julia Scarisbrick declared a non-personal specific non-financial interest as she was involved in related research studies with Takeda Ltd.
    - 8.1.1. It was agreed that this declaration would not prevent Julia Scarisbrick from participating in this section of the meeting.
  - 8.2. Sean Whittaker declared a non-personal specific non-financial interest as he was he was involved in a steering group for the condition.
    - 8.2.1. It was agreed that this declaration would not prevent Sean Whittaker from participating in this section of the meeting.
  - 8.3. Michael Chambers declared a personal specific financial interest as he has worked for Takeda Ltd as a contractor and did not attend this appraisal due to this conflict.
  - 8.4. No further conflicts of interest were declared for this appraisal.

### **Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

9. The committee discussed confidential information submitted as part of this appraisal.
10. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
11. The committee decision was based on consensus.

12. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD)

**Appraisal of Venetoclax with rituximab for treating relapsed or refractory chronic lymphocytic leukaemia [ID1097]**

**Part 1 – Open session**

13. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AbbVie Ltd.

14. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

- 14.1. Michael Chambers declared a non-personal non-specific financial interest as he participated in an advisory board for Roche, a comparator company in an unrelated area.

- 14.1.1. It was agreed that this declaration would not prevent Michael Chambers from participating in this section of the meeting.

- 14.2. Richard Nicholas declared a non-personal non-specific financial interest as he provided consultancy to Roche products which is a comparator company to develop products for multiple sclerosis.

- 14.2.1. It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.

- 14.3. Andrea Manca, Gail Coster, Kamal Balakrishnan and Rob Forsyth were not present for this appraisal discussion.

- 14.4. No further conflicts of interest were declared for this appraisal.

**Part 2 – Closed session (company representatives, ERG representatives and members of the public were asked to leave the meeting)**

15. The committee discussed confidential information submitted as part of this appraisal.

16. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.

17. The committee decision was based on consensus.

18. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

Tuesday 5 February 2019 from 10am to 5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.